Edition:
United States

Allena Pharmaceuticals Inc (ALNA.OQ)

ALNA.OQ on NASDAQ Stock Exchange Global Select Market

14.25USD
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
$14.25
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
--
52-wk High
$15.40
52-wk Low
$8.66

Summary

Name Age Since Current Position

Louis Brenner

44 2017 President, Chief Operating Officer

Alexey Margolin

63 2016 Chief Executive Officer, Co-Founder, Director

Hugh Wight

Vice President - Technical Operations

Stephen Kraus

38 Director

Bob Tepper

Director

Biographies

Name Description

Louis Brenner

Dr. Louis Brenner, M.D., is President, Chief Operating Officer of Allena Pharmaceuticals, Inc. Louis Brenner, M.D. has served as our chief operating officer since April 2015 and our president since February 2017. Dr. Brenner has more than a decade of industry leadership experience, including pharmaceutical development strategy, regulatory affairs, business development and marketing. From January 2014 to April 2015, Dr. Brenner served as senior vice president and chief medical officer at Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Dr. Brenner served as chief medical officer for Radius Health, Inc. (NASDAQ: RDUS), a biopharmaceutical company, from November 2011 to January 2014. Dr. Brenner has designed, planned and directed successful clinical trials at all stages and in multiple indications. He also serves on the board of directors of Goldfinch Biopharma Inc., a privately held biotechnology company. Dr. Brenner earned a B.S. from Yale University, an M.D. from Duke University and an M.B.A. from Harvard Business School. He completed his residency in internal medicine at Brigham and Women’s Hospital and his fellowship in nephrology at Brigham and Women’s Hospital and Massachusetts General Hospital. Dr. Brenner holds a clinical appointment at Brigham and Women’s Hospital.

Alexey Margolin

Dr. Alexey L. Margolin, Ph.D. is Chief Executive Officer, Co-Founder, Director of Allena Pharmaceuticals Inc. He also currently serves as co-founder, president and CEO of Alcresta. Prior to Allena and Alcresta, Dr. Margolin co-founded Alnara Pharmaceuticals in 2008, where he served as CEO until 2010 when the company was acquired by Eli Lilly and Company. Dr. Margolin also served as chief scientific officer and senior vice president of research & pre-clinical development of Altus Pharmaceuticals, Inc. Dr. Margolin is an expert in the fields of drug development, protein stabilization, crystallization and biocatalysis. He is the author of more than 60 publications and is an inventor on several patents in these areas. In 2003, Dr. Margolin was elected fellow of the American Institute of Medicine and Biological Engineering. Dr. Margolin holds both his M.S. in chemistry and Ph.D. in bio-organic chemistry from Moscow University.

Hugh Wight

Mr. Hugh Wight is Vice President - Technical Operations of Allena Pharmaceuticals Inc. Mr. Wight is an experienced manufacturing executive with more than 20 years in pharmaceutical and biopharmaceutical development, manufacturing, validation and quality assurance. Prior to joining Allena, Mr. Wight was vice president, technical operations for Alnara Pharmaceuticals, where he was responsible for manufacturing, project management, quality assurance and control, and managed strategic relationships with contract manufacturing organizations. Prior to that, Mr. Wight held various quality assurance and validation leadership positions at Altus Pharmaceuticals, Alkermes, Aquila Biopharmaceuticals, AutoImmune and InSite Vision. Mr. Wight holds a B.S. in microbiology from the University of Maine-Orono.

Stephen Kraus

Mr. Stephen Kraus is Director of Allena Pharmaceuticals, Inc. Mr. Kraus has served as an investment professional at Bessemer Venture Partners, or BVP, a venture capital firm, since 2004 and has been a partner since 2011. He served on the board of directors of FlexPharma, Inc. (NASDAQ: FLKS) from April 2014 to January 2015, of Ovascience, Inc. (NASDAQ: OVAS) from July 2011 to December 2014 and of a number of privately-held life sciences companies. He previously served as a member of the board of directors of Verastem, Inc. (NASDAQ: VSTM) from November 2010 to November 2012, Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT) from 2005 to 2007 and Restore Medical, Inc. (NASDAQ: REST) from 2005 to 2008. He holds an M.B.A. from Harvard Business School and a B.A. from Yale University. We believe that Mr. Kraus is qualified to serve on our board of directors due to his experience in the life sciences industry as a venture capitalist and his service on the boards of directors of other life sciences companies.

Bob Tepper

Dr. Bob Tepper, M.D. is Director of Allena Pharmaceuticals, Inc. Dr. Tepper is a partner of Third Rock Ventures, L.P., or Third Rock, which he co-founded in March 2007 and focuses on the formation, development and scientific strategy of Third Rock’s portfolio companies, as well as actively identifying and evaluating new investments. Prior to joining Third Rock, Dr. Tepper served as president of research and development at Millennium Pharmaceuticals, Inc. Dr. Tepper serves as an adjunct faculty member at Harvard Medical School and Massachusetts General Hospital and is an advisory board member of several healthcare institutions, including the Partners HealthCare Center for Personalized Genetic Medicine, Harvard Medical School and Tufts Medical School. Dr. Tepper is a board member of the public companies Jounce Therapeutics, Inc. (NASDAQ: JNCE) and Kala Pharmaceuticals, Inc. (NASDAQ: KALA) and various private life sciences companies. Dr. Tepper was previously a board member of the public company bluebird bio, Inc. (NASDAQ: BLUE). Dr. Tepper also serves on the board of overseers at Tufts University and on the Council of the National Center for Advancing Translational Sciences at the National Institutes of Health. Dr. Tepper holds an A.B. in biochemistry from Princeton University and an M.D. from Harvard Medical School. We believe that Dr. Tepper’s experience in the venture capital industry, particularly with biotech and pharmaceutical companies, combined with his experience building and operating research and development operations, on the boards of public and private life sciences companies and as faculty and advisory board member of several healthcare institutions, qualify him to serve as a member of our board of directors.

Basic Compensation

Options Compensation